QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O'Donnell, J. P. Articles by Obach, R. S. Search for Related Content PubMed PubMed Citation Articles by O'Donnell, J. P. Articles by Obach, R. S.

MECHANISM-BASED INACTIVATION OF HUMAN RECOMBINANT P450 2C9 BY THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG SUPROFEN

Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research and Development, Groton, Connecticut

The nonsteroidal anti-inflammatory agent (±)-suprofen [-methyl-4-(2-thienylcarbonyl)benzeneacetic acid] was evaluated as a P450 2C9 inactivator. (±)-Suprofen inactivated the diclofenac-4-hydroxylase activity of baculovirus-expressed P450 2C9 in a time- and concentration-dependent manner, which was consistent with mechanism-based inactivation. The loss of activity followed pseudo-first-order kinetics and was suprofen- and NADPH-dependent. The kinetic parameters for inactivation k_inact and K_I were 0.091 min^-1 and 3.7 µM, respectively, and the partition ratio was 101. Although P450 2C9 substrate S-warfarin partially protected against inactivation, reactive oxygen scavengers such as superoxide dismutase and catalase did not prevent inactivation. Extensive dialysis did not regenerate enzyme activity, suggesting that inactivation proceeded via covalent modification. Inactivated P450 2C9 lost <10% of its ability to form a CO-reduced complex, suggesting that inactivation may have resulted from covalent modification of apoprotein. Addition of exogenous nucleophiles such as glutathione and semicarbazide partially protected against inactivation. Apart from the metabolism of suprofen to 5-hydroxysuprofen, the formation of a suprofen-glutathione conjugate was also discernible in microsomal mixtures containing glutathione. Time of flight mass spectrometry revealed a protonated monoisotopic mass of 566.1304 for this conjugate, consistent with an elemental composition of C₂₄H₂₈N₃O₉S₂. The mass spectrum indicated that conjugation had occurred on the intact thiophene ring, presumably via a thioether linkage. Further evidence for the formation of an electrophilic intermediate in suprofen-P450 2C9 incubations was obtained via the characterization of a novel pyridazine adduct upon addition of semicarbazide to the microsomal mixtures. The pyridazine derivative had a protonated monoisotopic mass of 257.0895 that was consistent with an elemental composition of C₁₄H₁₃O₃N₂. The formation of the stable pyridazine adduct suggested the generation of an electrophilic -thioketo-, ß-unsaturated aldehyde, analogous to that observed during the cytochrome P450-mediated bioactivation of furan. This electrophilic , ß-unsaturated aldehyde represents a possible reactive intermediate that bioalkylates P450 2C9.

This article has been cited by other articles:

				J. M. Hutzler, L. M. Balogh, M. Zientek, V. Kumar, and T. S. Tracy Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and ({+/-})-Suprofen: A Comparison of Kinetics and Probe Substrate Selection Drug Metab. Dispos., January 1, 2009; 37(1): 59 - 65. [Abstract] [Full Text] [PDF]

				E. E. Graham, R. J. Walsh, C. M. Hirst, J. L. Maggs, S. Martin, M. J. Wild, I. D. Wilson, J. R. Harding, J. G. Kenna, R. M. Peter, et al. Identification of the Thiophene Ring of Methapyrilene as a Novel Bioactivation-Dependent Hepatic Toxicophore J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 657 - 671. [Abstract] [Full Text] [PDF]

				H.-K. Lim, N. Duczak Jr., L. Brougham, M. Elliot, K. Patel, and K. Chan AUTOMATED SCREENING WITH CONFIRMATION OF MECHANISM-BASED INACTIVATION OF CYP3A4, CYP2C9, CYP2C19, CYP2D6, AND CYP1A2 IN POOLED HUMAN LIVER MICROSOMES Drug Metab. Dispos., August 1, 2005; 33(8): 1211 - 1219. [Abstract] [Full Text] [PDF]

				T. M. Polasek, D. J. Elliot, B. C. Lewis, and J. O. Miners Mechanism-Based Inactivation of Human Cytochrome P4502C8 by Drugs in Vitro J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 996 - 1007. [Abstract] [Full Text] [PDF]